These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37092336)

  • 21. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
    Gross E; Rothstein M; Dombek S; Juknis HI
    Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenesis and management of intradialytic hypertension.
    Dousdampanis P; Trigka K; Giannopoulos A; Fourtounas C
    Curr Hypertens Rev; 2014; 10(3):171-6. PubMed ID: 25563732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interdialytic ambulatory blood pressure in patients with intradialytic hypertension.
    Van Buren PN; Toto R; Inrig JK
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):15-23. PubMed ID: 22123207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review on randomized control trials on rennin angiotensin aldosterone system inhibitors role in managing hypertension among hemodialysis patients.
    Aftab RA; Khan AH; Adnan AS; Jannah N
    Ren Fail; 2016; 38(3):474-80. PubMed ID: 26853680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between sympathetic activity, plasma concentrations of renin, aldosterone, and parathyroid hormone, and the degree of intractability of blood pressure control in modialysis patients.
    Hong ZR; Gil HW; Yang JO; Lee EY; Ahn JO; Hong SY
    J Korean Med Sci; 2007 Aug; 22(4):604-10. PubMed ID: 17728496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood pressure targets for hemodialysis patients.
    Turner JM; Peixoto AJ
    Kidney Int; 2017 Oct; 92(4):816-823. PubMed ID: 28938954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation and Treatment of Hypertension in End-Stage Renal Disease Patients on Hemodialysis.
    Van Buren PN
    Curr Cardiol Rep; 2016 Dec; 18(12):125. PubMed ID: 27796862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mechanisms of hypertension in patients with terminal kidney failure on programmed hemodialysis].
    Krimkevich EI; Petrun' NM; Baran EIa; Kutsaĭ NN; Khomenko NV
    Ter Arkh; 1986; 58(8):81-4. PubMed ID: 3020729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis.
    Sato A; Funder JW; Saruta T
    Am J Hypertens; 1999 Sep; 12(9 Pt 1):867-73. PubMed ID: 10509543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systolic blood pressure and mortality in patients on hemodialysis.
    Chang TI
    Curr Hypertens Rep; 2011 Oct; 13(5):362-9. PubMed ID: 21800233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversed association between aldosterone and mortality in hemodialysis patients: Role of volume overload.
    Hung SC; Tarng DC
    Steroids; 2016 Jul; 111():60-62. PubMed ID: 26826322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin-converting enzyme inhibitor and anemia in a patient undergoing hemodialysis.
    Yoshida A; Morozumi K; Suganuma T; Aoki J; Sugito K; Nakamura S; Ikeda M; Oikawa T; Fujinami T; Kawahara H
    Nephron; 1991; 59(2):334-5. PubMed ID: 1956504
    [No Abstract]   [Full Text] [Related]  

  • 33. Hypertension in chronic dialysis patients: pathophysiology, monitoring, and treatment.
    Morse SA; Dang A; Thakur V; Zhang R; Reisin E
    Am J Med Sci; 2003 Apr; 325(4):194-201. PubMed ID: 12695724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study.
    Shavit L; Neykin D; Lifschitz M; Slotki I
    Clin Nephrol; 2011 Nov; 76(5):388-95. PubMed ID: 22000559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognostic significance of controlled and uncontrolled arterial hypertension in patients with terminal kidney failure on chronic hemodialysis].
    Milovanova LIu; Nikolaev AIu; Lifshits NL; Milovanov IuS
    Ter Arkh; 2002; 74(6):45-9. PubMed ID: 12136483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of erythropoietin treatment on blood pressure and intracellular cation concentrations in maintenance hemodialysis patients.
    Okura Y; Oshima T; Yasunobu Y; Amano K; Mori M; Shinozaki K; Kajiyama G
    Hypertens Res; 1996 Jun; 19(2):91-5. PubMed ID: 10968201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Arterial hypertension and maintenance hemodialysis: effects of specific inhibition of angiotensin II by saralasin acetate].
    Mimran A; Deschodt G; Shaldon S; Barjon P; Mion C
    Arch Mal Coeur Vaiss; 1978 Jul; 71 Spec No():19-24. PubMed ID: 101176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension: A Scientific Statement from the American Heart Association and the American College of Cardiology.
    Black HR; Sica D; Ferdinand K; White WB;
    Circulation; 2015 Dec; 132(22):e298-302. PubMed ID: 26621647
    [No Abstract]   [Full Text] [Related]  

  • 39. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis.
    Klassen PS; Lowrie EG; Reddan DN; DeLong ER; Coladonato JA; Szczech LA; Lazarus JM; Owen WF
    JAMA; 2002 Mar; 287(12):1548-55. PubMed ID: 11911757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sympathetic overactivity in patients with chronic renal failure.
    Converse RL; Jacobsen TN; Toto RD; Jost CM; Cosentino F; Fouad-Tarazi F; Victor RG
    N Engl J Med; 1992 Dec; 327(27):1912-8. PubMed ID: 1454086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.